Mechanism of Selective Inhibition of Respiratory Syncytial Virus by a Benzodithiin Compound (RD3–0028)

Microbiology and Immunology - Tập 45 Số 7 - Trang 531-537 - 2001
Kenji Sudo1,2, Kenji Konno2, Wataru Watanabe2, Shirô Shigeta1, Tomoyuki Yokota2
1Department of Microbiology, Fukushima University School of Medicine, Fukushima, Fukushima, 960-1295 Japan
2Rational Drug Design Laboratories, Fukushima, Fukushima, 960-1242 Japan

Tóm tắt

AbstractRD3–0028, a compound with a benzodithiin structure, was found to be a potent inhibitor of respiratory syncytial virus (RSV) replication. Its action is specific; no activity is seen against influenza A virus, measles virus, herpes simplex virus type 1 or 2, or human cytomegalovirus. A time‐dependent drug addition experiment indicated that the antiviral activity occurs in the late stage of the RSV replication cycle, since this compound completely inhibited syncytium formation even when added up to 16 hr after the infection of cell monolayers at an MOI of 3. RD3–0028 had no direct virucidal effect on RSV. Western blotting analysis showed that RD3–0028 significantly decreased the amount of RSV proteins released into the cell culture medium. Moreover, five independent isolates of the RSV long strain were selected for growth in RD3–0028 (5–20 μg/ml). These resistant viruses were more than 80‐fold less sensitive to RD3–0028 than the long strain. The F gene segment of each of these viruses was sequenced and in each case the mutant RNA segment contained at least one sequence alteration, converting asparagine 276 to tyrosine (F1 protein). These results suggest that RD3–0028 inhibits RSV replication by interfering with intracellular processing of the RSV fusion protein, or a step immediately thereafter, leading to loss of infectivity.

Từ khóa


Tài liệu tham khảo

10.1073/pnas.94.5.1937

10.1073/pnas.93.1.81

Committee on Infectious Diseases, American Academy of Pediatrics, 1993, Use of ribavirin in the treatment of respiratory syncytial virus infection, Pediatrics, 92, 501, 10.1542/peds.92.3.501

10.1073/pnas.91.4.1386

10.1099/0022-1317-66-9-1983

10.1128/AAC.35.7.1469

Groothuis J.R., The Respiratory Syncytial Virus Immune Globulin Study Group. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high‐risk infants and young children, N. Engl. J. Med., 329, 1524

10.1099/0022-1317-66-6-1241

10.1126/science.7915433

10.1016/0264-410X(95)98263-A

10.1128/AAC.38.2.256

10.1073/pnas.93.5.2186

McGinnes L.W., 1985, Conformational changes in Newcastle disease virus fusion glycoprotein during intracellular transport, J. Virol., 56, 341, 10.1128/jvi.56.2.341-348.1985

10.1073/pnas.84.4.1020

10.1016/0168-1702(85)90045-0

Pringle C.R., 1987, Progress towards control of the acute respiratory viral diseases of childhood, Bull. WHO, 65, 133

10.1177/095632029500600607

10.1097/00006454-199809000-00007

10.1128/AAC.36.2.435

Shigeta S., 1995, In vitro antimyxovirus and anti‐human immunodeficiency virus activities of polyoxometalates, Antiviral Res., 6, 114

10.1021/jm00080a018

10.1128/jvi.61.12.3855-3861.1987

Sudo K., 1999, Efficacy of RD3–0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice, Antimicrob. Agents Chemother., 43, 752, 10.1128/AAC.43.4.752

Taylor G., 1984, Monoclonal antibodies protect against respiratory syncytial virus infection in mice, Immunology, 52, 137

10.1099/0022-1317-73-9-2217

10.1099/0022-1317-67-3-505

10.1016/0166-0934(94)90124-4

10.1006/bbrc.1998.9222

Thông tin
Thông tin xuất bản

Microbiology and Immunology

Tập 45 Số 7

531-537

Thông tin tác giả